ZIYUANYUAN HOLDINGS GROUP LIMITED 紫 元 元 控 股 集 團 有 限 公 司 (Incorporated in the Cayman Islands with limited liability) (於関曼群島註冊成立的有限公司) Stock code股份代號：8223 2024 Interim Report 中期報告 omission of which would make any statement herein or this report misleading. CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed ...

1 Ziyuanyuan Holdings Group Limited 紫元元控股集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：8223） 截至二零二四年六月三十日止六個月 中期業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM乃為較於聯交所上市的其他公司可能帶有更高投資風險的中小型公司而設的市場。有意 投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，於GEM買賣的證券可能會較於聯交所主板買賣的證 券承受較大的市場波動風險，同時無法保證於GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 本公告乃遵照聯交所GEM證券上市規則（「GEM上市規則」）的規定而提供有關紫元元控股集 團有限公司（「本公司」）的資料，本公司之董事（「董事」）願就本公告共同及個別地承擔全部責 任。董事在作出一切合理查詢後，確認就彼等所知及所信，本公告所載資料在各重要方 ...

(a) the policies; and (b) 遵守對發行人有重大影響的相關法律及規例的資料 against the issuer or its employees during the Reporting Period and B7.2 Description of preventive measures and whistleblowing procedures, B7.3 描述向董事及員工提供的反貪污培訓 社區利益的政策 B8.2 在專注範疇所動用資源 The Board is pleased to present its annual report together with the audited consolidated financial statements of the Group for the Year. The results of the Group for the Year and the financial position of the Company and of the Group at that date are set out in the consolidated ...

Revenue and Profit - Total revenue for 2023 reached RMB 497,955 thousand, with the trade business contributing RMB 416,998 thousand, accounting for the largest share[8] - The company's net profit attributable to equity holders was RMB 312,447 thousand in 2023, compared to RMB 306,861 thousand in 2022[6] - The company's trade business revenue grew significantly to RMB 416,998 thousand in 2023 from RMB 236,539 thousand in 2022, representing a 76.2% increase[25] - Total revenue increased to RMB 497.955 million in 2023, up from RMB 324.598 million in 2022, driven by growth in medical equipment and consumables trade revenue, which rose to RMB 416.998 million from RMB 236.539 million[82] - Revenue increased by approximately RMB 173.4 million or 53.4%, from RMB 324.6 million in the previous year to RMB 498.0 million in the current year, primarily driven by growth in medical equipment and consumables trade revenue, which rose from RMB 236.5 million to RMB 417.0 million[120] - Medical device and consumables trade business revenue reached RMB 417.0 million for the year[128] - Net profit attributable to the company's owners decreased to RMB 14.563 million in 2023, compared to RMB 15.813 million in 2022[82] - The company's profit attributable to owners for the year was approximately RMB 14.6 million, a decrease from RMB 15.8 million in the previous year[139] Assets and Liabilities - Total assets minus current liabilities increased to RMB 406,509 thousand in 2023 from RMB 355,232 thousand in 2022[3] - The company's total liabilities stood at RMB 299,874 thousand as of December 31, 2023[15] - The company's total assets stood at RMB 615,163 thousand, while total liabilities were RMB 291,460 thousand, reflecting a strong balance sheet position[48][71] - The company's total assets stood at RMB 602.277 million, with cash and bank balances increasing significantly to RMB 108.260 million in 2023 from RMB 13.707 million in 2022[83][94] - The company's total assets across reportable segments amounted to RMB 579.269 million, with the largest segment contributing RMB 349.699 million[124] - Net current assets decreased to RMB 199,640 thousand from RMB 233,689 thousand[188] - Non-current liabilities decreased to RMB 39,943 thousand from RMB 95,692 thousand, with bank and other borrowings dropping to RMB 31,754 thousand from RMB 80,981 thousand[189] - Net asset value increased to RMB 315,289 thousand from RMB 310,817 thousand[189] - Reserves increased to RMB 278,608 thousand from RMB 273,022 thousand[189] - Total equity increased to RMB 315,289 thousand from RMB 310,817 thousand[189] Trade and Receivables - The company's trade receivables aged 1-30 days increased to RMB 162,587 thousand in 2023 from RMB 95,482 thousand in 2022[39] - The company's trade receivables increased from RMB 137,955 thousand in 2022 to RMB 206,411 thousand in 2023, with a corresponding increase in impairment loss provisions from RMB 5,520 thousand to RMB 9,424 thousand[58] - Trade receivables increased to RMB 196.987 million in 2023, up from RMB 132.435 million in 2022, reflecting growth in business activities[83] Maternity Services - The company's maternity services revenue decreased to RMB 28,438 thousand in 2023 from RMB 50,809 thousand in 2022, a 44% decline[25] - Revenue from maternity services decreased to RMB 28.438 million in 2023, down from RMB 50.809 million in 2022, primarily due to pandemic-related restrictions and the closure of 3 maternity centers[82] - The company recorded a segment loss of RMB 5.9 million in the maternity services sector, attributed to operational disruptions and center closures[73] - The company acquired a 51% equity stake in Wuhan Desheng Meimei Health Management Co., Ltd. for RMB 3.4 million, expanding its maternity services portfolio[73] - The maternity services sector is expected to benefit from China's three-child policy, with over 90% of consumers recognizing the professionalism of maternity centers[99] - The company plans to enhance its maternity services through digitalization and intelligent upgrades, aiming to build a comprehensive maternal and infant ecosystem[99] Financing and Leases - The company's bank and other borrowings decreased to RMB 101,047 thousand in 2023 from RMB 147,861 thousand in 2022[17] - The company's financing lease receivables decreased from RMB 201,072 thousand in 2022 to RMB 131,469 thousand in 2023, reflecting a significant reduction in lease obligations[44] - The company provided financing lease services to approximately 4,800 SME clients across 30 provinces, cities, and autonomous regions in China, generating revenue of RMB 25.1 million in 2023[53] - Total bank and other borrowings decreased from RMB 228,842 thousand in 2022 to RMB 132,801 thousand in 2023, indicating a reduction in debt[52] - The company's financing costs for 2023 included RMB 12,447 thousand in bank and other borrowing interest, and RMB 1,400 thousand in lease liability interest[56] - The company's lease liabilities were recorded at RMB 3.453 million[127] - Total financing lease receivables and loan receivables were approximately RMB 72.1 million as of December 31, 2023 (2022: RMB 143.5 million)[131] - Bank and other borrowings due within one year decreased to approximately RMB 101.0 million (2022: RMB 147.9 million), and borrowings due after one year decreased to approximately RMB 31.8 million (2022: RMB 80.9 million)[151] - The asset-liability ratio decreased to approximately 29.6% (2022: 42.4%), mainly due to reduced demand for bank and other borrowings as a result of the decrease in the group's finance lease business[164] Costs and Expenses - The company's R&D costs recognized as expenses were RMB 3,091 thousand in 2023, down from RMB 4,080 thousand in 2022[9] - The company's short-term lease expenses decreased to RMB 1,061 thousand in 2023 from RMB 5,486 thousand in 2022[9] - Sales cost for medical equipment and consumables trade increased from RMB 185.6 million in the previous year to RMB 375.0 million in the current year[109] - The company's employee costs decreased from RMB 42.0 million in the previous year to RMB 38.7 million in the current year[121] - The total employee cost for the year was approximately RMB 41.6 million (2022: RMB 45.8 million), with employee retirement benefit expenses of approximately RMB 4.7 million (2022: RMB 6.0 million)[167] - Other operating expenses decreased from approximately RMB 55.4 million in the previous year to approximately RMB 46.0 million this year, mainly due to reductions in miscellaneous expenses for the maternal and infant business, short-term lease payments, and depreciation of right-of-use assets[149] Investments and Acquisitions - The company acquired a 51% equity stake in Wuhan Desheng Meimei Health Management Co., Ltd. for RMB 3.4 million, expanding its maternity services portfolio[73] - The company entered into a share transfer agreement to acquire Wuhan Meikangmao Health Management Co., Ltd. for RMB 40.0 million, though the transaction has not yet been completed as of December 31, 2023[143] - The group did not engage in any significant acquisitions or disposals of subsidiaries or associates during the year[154] Dividends and Share Capital - The company declared a final dividend of 2.5 HK cents per share for the year, consistent with the previous year's dividend[87] - No final dividend is recommended for the year ended December 31, 2023 (2022: 2.5 HK cents)[173] - The company's issued share capital was HKD 40,000,000 with 400,000,000 ordinary shares issued as of December 31, 2023[141] - The group's capital structure remains unchanged since its listing on the GEM of the Hong Kong Stock Exchange on July 9, 2018, with only ordinary shares in its share capital[165] Impairment and Losses - The company recorded a goodwill impairment loss of RMB 1.2 million due to the underperformance of one of its subsidiaries, Guangzhou Shengcheng Dunnan Enterprise Management Co., Ltd., and the closure of one of its maternity centers[117] - Additional impairment loss of approximately RMB 6.0 million was recognized this year (2022: RMB 9.2 million), primarily due to increased customer delinquency rates caused by the COVID-19 pandemic[149] Other Financial Information - The company's deferred tax liabilities amounted to RMB 4,041 thousand, indicating future tax obligations[47] - The company's profit before tax for 2023 was RMB 18,001 thousand, with a fair value loss on investment properties of RMB 600 thousand[64] - The company's cash and bank balances were reported at RMB 67 thousand, showing a minimal liquidity position[65] - The company's other income from sources outside its core operations was RMB 25,900 thousand in 2023, down from RMB 37,250 thousand in 2022[70] - The company's deferred tax assets amounted to RMB 9.52 million[126] - The company's other financial assets were valued at RMB 847 thousand[104] - The company's prepayments, deposits, and other receivables amounted to RMB 1.262 million[112] - Capital commitments for subsidiary acquisitions and computer software purchases amounted to RMB 18.8 million as of December 31, 2023 (2022: RMB 13.5 million)[130] - The company completed a share subscription of 30,000,000 shares at HKD 1.47 per share, raising net proceeds of approximately HKD 43.5 million for general working capital and business development[134] - Bank balances and cash stood at approximately RMB 108.3 million as of December 31, 2023 (2022: RMB 13.7 million)[139] - The group's non-current assets include property, plant, and equipment valued at RMB 7,232 million (2022: RMB 9,786 million) and investment properties valued at RMB 24,400 million (2022: RMB 25,000 million)[187] - Investment properties valued at RMB 25,000 thousand[196] - Financing costs amounted to RMB (13,872) thousand[192] Corporate Governance and Meetings - The company will hold its Annual General Meeting on May 31, 2024, with share transfer registration suspended from May 28 to May 31, 2024[197] - The annual results announcement is available on the HKEX website and the company's website, with the annual report to be distributed to shareholders and published online in due course[198] Workforce - The group had 184 employees as of December 31, 2023 (2022: 281 employees), reflecting a reduction in workforce[167]

其他經營開支 其他經營開支主要包括法律及專業費用、辦 公用品、物業、廠房及設備折舊、使用權資 產折舊、短期租賃付款、確認為開支的研發 成本、銷售和營銷費用及母嬰月子業務的雜 項費用。其他經營開支由先前期間的約人民 幣41.9百萬元減少至本期間的約人民幣31.6 百萬元。減少主要歸因於(i)母嬰月子業務的 雜項費用由先前期間的約人民幣11.3百萬元 減少至本期間的約人民幣4.2百萬元；(ii)短期 租賃付款由先前期間的約人民幣4.6百萬元 減少至本期間的約人民幣1.1百萬元；及(iii) 物業、廠房及設備的折舊由先前期間的約人 民幣3.7百萬元減少至本期間的約人民幣3.1 百萬元，其抵銷銷售和營銷費用由人民幣 4.4百萬元增加至人民幣6.7百萬元。 Income tax expenses 16 ZIYUANYUAN HOLDINGS GROUP LIMITED THIRD QUARTERLY REPORT 2023 DISCLOSURE OF INTEREST 董事及主要行政人員於本公司及其相聯法 團的股份、相關股份及債權證的權益及淡倉 | --- | --- | --- | --- | |---------- ...

Ziyuanyuan Holdings Group Limited 紫元元控股集團有限公司 （於開曼群島註冊成立的有限公司） 8223 （股份代號： ） 截至二零二三年九月三十日止九個月 第三季度業績公告 GEM 香港聯合交易所有限公司（「聯交所」） 的特色 GEM 乃為較於聯交所上市的其他公司可能帶有更高投資風險的中小型公司而設的市場。有意 投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳考慮後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，於 買賣的證券可能會較於聯交所主板買賣的證 GEM 券承受較大的市場波動風險，同時無法保證於 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 GEM GEM 本公告乃遵照聯交所 證券上市規則（「 上市規則」）的規定而提供有關紫元元控股集 團有限公司（「本公司」）的資料，本公司之董事（「董事」）願就本公告共同及個別地承擔全部責 任。董事在作出一切合理查詢後，確認就彼等所知及 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 Ziyuanyuan Holdings Group Limited 紫元元控股集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：8223） 有關截至二零二二年十二月三十一日止年度 之年報的補充公告 茲提述紫元元控股集團有限公司（「本公司」）及其附屬公司（統稱「本集團」)截至二零二二 年十二月三十一日止年度的年報（「二零二二年年報」）。本公告為對二零二二年年報的補充， 並應與二零二二年年報一併閱讀。除另有界定外，本公告所用詞彙與二零二二年年報所界定者具 有相同涵義。 除二零二二年年報內所披露的資料外，本公司董事會（「董事會」）謹此提供有關本集團融資租 賃服務的進一步資料： 風險管理政策 本集團在提供融資租賃服務中會面臨多種風險，包括信貸風險、流動資金風險、利率風險、營運 風險及法律及合規風險。本集團認識到有效風險管理系統對識別及降低該等風險的重要性。本集 ...

Finance leasing services 紫元元控股集團有限公司（「本公司」）董事 （「董事」）會（「董事會」）公佈本公司及其附 屬公司（統稱「本集團」)截至二零二三年六月 三十日止六個月（「本期間」)的未經審核簡 明綜合中期業績，連同二零二二年相應期間 （「先前期間」）的比較數字。 母嬰月子產業服務 Due to the restriction of the epidemic control measures, the Group's postpartum care centers were not able to operate normally during part of the Period, which made customers unable to check in on time and orders were returned, resulting in a decline in revenue and recorded a segmental loss in the maternal and child postpartum care industry services. The ...

Ziyuanyuan Holdings Group Limited 紫元元控股集團有限公司 （於開曼群島註冊成立的有限公司） 8223 （股份代號： ） 截至二零二三年六月三十日止六個月 中期業績公告 GEM 香港聯合交易所有限公司（「聯交所」） 的特色 GEM 乃為較於聯交所上市的其他公司可能帶有更高投資風險的中小型公司而設的市場。有意 投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳考慮後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，於 買賣的證券可能會較於聯交所主板買賣的證 GEM 券承受較大的市場波動風險，同時無法保證於 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不就因本報告全部或任何部份內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 GEM GEM 本公告乃遵照聯交所 證券上市規則（「 上市規則」）的規定而提供有關紫元元控股集 團有限公司（「本公司」）的資料，本公司之董事（「董事」）願就本報告共同及個別地承擔全部責 任。董事在作出一切合理查詢後，確認就彼等所知及所信 ...

ZIYUANYUAN HOLDINGS GROUP LIMITED 浆元元控股集團有限公司 第一季度報告 herein or this report misleading. EXCHANGE OF HONG KONG LIMITED (THE GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. | --- | --- | |----------- ...